Narendra D. Lalwani, Ph.D., FAHA, DABT
2017
In 2017, Narendra D. Lalwani, Ph.D., FAHA, DABT earned a total compensation of $1.2M as Executive Vice President, Research and Development and Chief Operating Officer at Esperion Therapeutics, a 80% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $203,000 |
|---|---|
| Option Awards | $643,978 |
| Salary | $390,000 |
| Other | $12,000 |
| Total | $1,248,978 |
DABT received $644K in option awards, accounting for 52% of the total pay in 2017.
DABT also received $203K in non-equity incentive plan, $390K in salary and $12K in other compensation.
Rankings
In 2017, Narendra D. Lalwani, Ph.D., FAHA, DABT's compensation ranked 7,912th out of 14,666 executives tracked by ExecPay. In other words, DABT earned more than 46.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,912 out of 14,666 | 46th |
Division Manufacturing | 2,968 out of 5,772 | 49th |
Major group Chemicals And Allied Products | 970 out of 2,075 | 53rd |
Industry group Drugs | 756 out of 1,731 | 56th |
Industry Pharmaceutical Preparations | 593 out of 1,333 | 56th |
Source: SEC filing on April 13, 2018.
DABT's colleagues
We found two more compensation records of executives who worked with Narendra D. Lalwani, Ph.D., FAHA, DABT at Esperion Therapeutics in 2017.